ClinicalTrials.gov
ClinicalTrials.gov Menu

Tranexamic Acid Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00375440
Recruitment Status : Withdrawn (Study halted prematurely as investigator left the institution.)
First Posted : September 13, 2006
Last Update Posted : October 5, 2015
Sponsor:
Information provided by:
Texas Tech University Health Sciences Center

Brief Summary:
The purpose of this study is to determine if tranexamic acid significantly reduces blood loss and blood transfusion in revision total hip replacement. Tranexamic acid is a drug that helps to reduce blood loss during surgery. Revision total hip replacement surgery is treatment for patients who have previously had hipe replacement surgery which failed and must be repaired/replaced.

Condition or disease Intervention/treatment Phase
Arthroplasty, Replacement, Hip Drug: Tranexamic Acid Not Applicable

Detailed Description:

Tranexamic acid is an anti-fibrinolytic agent that inhibits fibrinolysis leading to a reduction of blood loss without concurrently increasing the risk of thromboembolic complications. Several studies have shown that tranexamic acid reduces blood loss and blood transfusions in primary total hip and knee arthroplasty. However, there have not been any studies that evaluate its efficacy in revision total hip arthroplasty. The significance of this study is that the need for blood transfusions and their complications may be minimized in revision hip arthroplasty if tranexamic acid is found to significantly decrease the amount of blood transfusions.

After the patient has been consented, he or she will be randomized into one of two groups (tranexamic acid and placebo) by the School of Pharmacy. The placebo will be crystalloid fluid of equal volume as tranexamic acid. The patient will then undergo revision total hip arthroplasty by Dr. Rosenstein and be administered tranexamic acid or placebo. Blood loss will be recorded intraoperatively and postoperatively through drains. Criteria for blood transfusion include hemoglobin less than 10g/dl or hematocrit less than 30%. Once the operation ends, the drug or placebo will be discontinued and the postoperative care is unchanged from current standards/protocols. Intraoperative blood loss, total blood loss, and number of blood transfusions will be recorded and analyzed. Length of acute hospital stay will also be recorded. A cost analysis will be performed comparing tranexamic acid to blood transfusions.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty
Study Start Date : February 2005
Actual Primary Completion Date : January 2008
Actual Study Completion Date : January 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hip Replacement
U.S. FDA Resources




Primary Outcome Measures :
  1. Introperative blood loss
  2. Total blood loss
  3. Number of blood transfusions required

Secondary Outcome Measures :
  1. Length of acute hospital stay


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Failed primary total hip arthroplasty (femoral stem, acetabular component, or both)
  • 18-100 years of age

Exclusion Criteria:

  • Prosthetic infection
  • Primary total hip arthroplasty
  • Prisoners
  • Pregnancy
  • Previous adverse reaction to tranexamic acid
  • Bleeding/coagulation disorders
  • Renal insufficiency (serum creatinine>two standard deviations for age)
  • History of deep venous thrombosis or pulmonary embolism
  • Religious beliefs/practices prohibiting blood transfusions
  • Wards of the state
  • Cognitively impaired patients
  • Terminally ill patients
  • Students and/or employees
  • Color blindness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00375440


Locations
United States, Texas
Texas Tech University Health Sciences Center Department of Orthopaedic Surgery
Lubbock, Texas, United States, 79430
Sponsors and Collaborators
Texas Tech University Health Sciences Center
Investigators
Principal Investigator: Alexander D Rosenstein, MD Texas Tech University Health Sciences Center Department of Orthopaedic Surgery

Publications:

Responsible Party: Alexander Rosenstein, MD
ClinicalTrials.gov Identifier: NCT00375440     History of Changes
Other Study ID Numbers: L05-063
First Posted: September 13, 2006    Key Record Dates
Last Update Posted: October 5, 2015
Last Verified: October 2015

Keywords provided by Texas Tech University Health Sciences Center:
Tranexamic Acid
Revision Total Hip Replacement
Reduction in Blood Loss

Additional relevant MeSH terms:
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Hemostatics
Coagulants